Literature DB >> 33202305

Cellular reprogramming to model and study epigenetic alterations in cancer.

Jungsun Kim1.   

Abstract

Although genetic mutations are required for cancer development, reversible non-genetic alterations also play a pivotal role in cancer progression. Failure of well-orchestrated gene regulation by chromatin states and master transcription factors can be one such non-genetic etiology for cancer development. Master transcription factor-mediated cellular reprogramming of human cancer cells allows us to model cancer progression. Here I cover the history and recent advances in reprogramming cancer cells, followed by lessons from cellular reprogramming of normal cells that may apply to cancer. Lastly, I share my perspective on cellular reprogramming for studying epigenetic alterations that have occurred in tumorigenesis, discuss the current limitations, and propose ways to overcome the obstacles in the reprogramming of cancer.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2020        PMID: 33202305      PMCID: PMC7768185          DOI: 10.1016/j.scr.2020.102062

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  118 in total

1.  A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts.

Authors:  Ronghui Li; Jialiang Liang; Su Ni; Ting Zhou; Xiaobing Qing; Huapeng Li; Wenzhi He; Jiekai Chen; Feng Li; Qiang Zhuang; Baoming Qin; Jianyong Xu; Wen Li; Jiayin Yang; Yi Gan; Dajiang Qin; Shipeng Feng; Hong Song; Dongshan Yang; Biliang Zhang; Lingwen Zeng; Liangxue Lai; Miguel Angel Esteban; Duanqing Pei
Journal:  Cell Stem Cell       Date:  2010-06-17       Impact factor: 24.633

2.  Control of developmental regulators by Polycomb in human embryonic stem cells.

Authors:  Tong Ihn Lee; Richard G Jenner; Laurie A Boyer; Matthew G Guenther; Stuart S Levine; Roshan M Kumar; Brett Chevalier; Sarah E Johnstone; Megan F Cole; Kyo-ichi Isono; Haruhiko Koseki; Takuya Fuchikami; Kuniya Abe; Heather L Murray; Jacob P Zucker; Bingbing Yuan; George W Bell; Elizabeth Herbolsheimer; Nancy M Hannett; Kaiming Sun; Duncan T Odom; Arie P Otte; Thomas L Volkert; David P Bartel; Douglas A Melton; David K Gifford; Rudolf Jaenisch; Richard A Young
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

3.  A DEMONSTRATION OF THE RECOVERY OF THE CROWN-GALL TUMOR CELL WITH THE USE OF COMPLEX TUMORS OF SINGLE-CELL ORIGIN.

Authors:  A C Braun
Journal:  Proc Natl Acad Sci U S A       Date:  1959-07       Impact factor: 11.205

4.  A highly optimized protocol for reprogramming cancer cells to pluripotency using nonviral plasmid vectors.

Authors:  Hongzhi Zhao; Timothy J Davies; Jiaolin Ning; Yanxu Chang; Patty Sachamitr; Susanne Sattler; Paul J Fairchild; Fang-Ping Huang
Journal:  Cell Reprogram       Date:  2014-12-30       Impact factor: 1.987

5.  Genome-wide characterization of the routes to pluripotency.

Authors:  Samer M I Hussein; Mira C Puri; Peter D Tonge; Marco Benevento; Andrew J Corso; Jennifer L Clancy; Rowland Mosbergen; Mira Li; Dong-Sung Lee; Nicole Cloonan; David L A Wood; Javier Munoz; Robert Middleton; Othmar Korn; Hardip R Patel; Carl A White; Jong-Yeon Shin; Maely E Gauthier; Kim-Anh Lê Cao; Jong-Il Kim; Jessica C Mar; Nika Shakiba; William Ritchie; John E J Rasko; Sean M Grimmond; Peter W Zandstra; Christine A Wells; Thomas Preiss; Jeong-Sun Seo; Albert J R Heck; Ian M Rogers; Andras Nagy
Journal:  Nature       Date:  2014-12-11       Impact factor: 49.962

6.  Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Authors:  Andriana G Kotini; Chan-Jung Chang; Arthur Chow; Han Yuan; Tzu-Chieh Ho; Tiansu Wang; Shailee Vora; Alexander Solovyov; Chrystel Husser; Malgorzata Olszewska; Julie Teruya-Feldstein; Deepak Perumal; Virginia M Klimek; Alexandros Spyridonidis; Raajit K Rampal; Lewis Silverman; E Premkumar Reddy; Elli Papaemmanuil; Samir Parekh; Benjamin D Greenbaum; Christina S Leslie; Michael G Kharas; Eirini P Papapetrou
Journal:  Cell Stem Cell       Date:  2017-02-16       Impact factor: 24.633

7.  Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice.

Authors:  Takashi Sakatani; Atsushi Kaneda; Christine A Iacobuzio-Donahue; Mark G Carter; Sten de Boom Witzel; Hideyuki Okano; Minoru S H Ko; Rolf Ohlsson; Dan L Longo; Andrew P Feinberg
Journal:  Science       Date:  2005-02-24       Impact factor: 47.728

8.  Modeling familial cancer with induced pluripotent stem cells.

Authors:  Dung-Fang Lee; Jie Su; Huen Suk Kim; Betty Chang; Dmitri Papatsenko; Ruiying Zhao; Ye Yuan; Julian Gingold; Weiya Xia; Henia Darr; Razmik Mirzayans; Mien-Chie Hung; Christoph Schaniel; Ihor R Lemischka
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

9.  Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase.

Authors:  Yosef Buganim; Dina A Faddah; Albert W Cheng; Elena Itskovich; Styliani Markoulaki; Kibibi Ganz; Sandy L Klemm; Alexander van Oudenaarden; Rudolf Jaenisch
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

10.  Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells.

Authors:  Kran Suknuntha; Yuki Ishii; Lihong Tao; Kejin Hu; Brian E McIntosh; David Yang; Scott Swanson; Ron Stewart; Jean Y J Wang; James Thomson; Igor Slukvin
Journal:  Stem Cell Res       Date:  2015-10-31       Impact factor: 2.020

View more
  2 in total

1.  Epigenetic Inheritance From Normal Origin Cells Can Determine the Aggressive Biology of Tumor-Initiating Cells and Tumor Heterogeneity.

Authors:  Jiliang Feng; Dawei Zhao; Fudong Lv; Zhongyu Yuan
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

2.  An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool.

Authors:  Nasir Javaid; Sangdun Choi
Journal:  Stem Cells Int       Date:  2022-09-22       Impact factor: 5.131

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.